药物去势与最大限度雄激素阻断疗法在前列腺癌治疗中不良反应情况的meta分析
发布时间：2019-06-25 09:31
【摘要】：目的对药物去势（单用黄体生成素释放激素类似物）与最大限度雄激素阻断疗法（MAB）在前列腺癌治疗中的临床不良反应情况进行系统评价。 方法检索Pubmed，Embase，万方数据库，知网数据库等，检索前列腺癌药物治疗的随机对照试验（randomized controlled trials，RCTs）文献，依据文献纳入和排除标准，进行文献筛选，选采用Jadad量表对纳入文献进行质量评价。采用Stata软件进行荟萃分析（meta-analysis），对计量资料计算比值比（OR）与相应的95％可信区间（confidence interval，CI），并对潜在的发表偏倚做漏斗图。 结果按纳入标准筛选，，共纳入220个临床研究的1384例患者进行研究，涉及单用黄体生成素释放激素类似物和最大限度雄阻断治疗在前列腺癌患者治疗中产生不良反应等方面的比较。荟萃分析显示：经单用黄体生成素释放激素类似物治疗和MAB治疗后不良反应中全部症状、转氨酶增加、胃肠道毒性和潮热发生率等方面没有统计学差异。与MAB治疗相比，单用黄体生成素释放激素类似物治疗在严重并发症的发生率方面要高于MAB治疗（OR:0.23;95%CI:0.09-0.58）。 结论单用黄体生成素释放激素类似物（LHRH-a）与最大限度雄激素阻断疗法（MAB）两种疗法在用药后不良反应发生率方面并未有明显不同，但在严重并发症发生率方面MAB治疗可能存在一定优势。
[Abstract]:Objective to evaluate the clinical adverse reactions of drug castration (LH releasing hormone analogues alone) and maximum androgen blocking therapy (MAB) in the treatment of prostate cancer. Methods Pubmed,Embase, Wanfang database, knowledge network database and (randomized controlled trials,RCTs were searched for prostate cancer drug therapy. According to the criteria of literature inclusion and exclusion, the literature was screened, and the quality of the included literature was evaluated by Jadad scale. Meta-analysis (meta-analysis) was carried out by Stata software, and the ratio (OR) to the corresponding 95% confidence interval (confidence interval,CI) was calculated, and the funnel diagram of the potential publication bias was made. Results A total of 1384 patients were selected according to the inclusion criteria, involving the comparison of the adverse reactions of patients with prostate cancer treated with LH releasing hormone analogues alone and the maximum male blocking therapy. Meta-analysis showed that there was no significant difference in all the adverse reactions, the increase of transaminase, gastrointestinal toxicity and the incidence of hot flashes after treatment with LH-releasing hormone analogues and MAB alone. Compared with MAB, the incidence of serious complications was higher in the treatment of LH-releasing hormone analogues than in the treatment of MAB (OR:0.23;95%CI:0.09-0.58). Conclusion there is no significant difference in the incidence of adverse reactions between LHRH-a alone and (MAB), but MAB may have some advantages in the incidence of severe complications.
【学位授予单位】：苏州大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.25
本文编号：2505583
[Abstract]:Objective to evaluate the clinical adverse reactions of drug castration (LH releasing hormone analogues alone) and maximum androgen blocking therapy (MAB) in the treatment of prostate cancer. Methods Pubmed,Embase, Wanfang database, knowledge network database and (randomized controlled trials,RCTs were searched for prostate cancer drug therapy. According to the criteria of literature inclusion and exclusion, the literature was screened, and the quality of the included literature was evaluated by Jadad scale. Meta-analysis (meta-analysis) was carried out by Stata software, and the ratio (OR) to the corresponding 95% confidence interval (confidence interval,CI) was calculated, and the funnel diagram of the potential publication bias was made. Results A total of 1384 patients were selected according to the inclusion criteria, involving the comparison of the adverse reactions of patients with prostate cancer treated with LH releasing hormone analogues alone and the maximum male blocking therapy. Meta-analysis showed that there was no significant difference in all the adverse reactions, the increase of transaminase, gastrointestinal toxicity and the incidence of hot flashes after treatment with LH-releasing hormone analogues and MAB alone. Compared with MAB, the incidence of serious complications was higher in the treatment of LH-releasing hormone analogues than in the treatment of MAB (OR:0.23;95%CI:0.09-0.58). Conclusion there is no significant difference in the incidence of adverse reactions between LHRH-a alone and (MAB), but MAB may have some advantages in the incidence of severe complications.
【学位授予单位】：苏州大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.25
【参考文献】
中国期刊全文数据库 前4条
1 高江平,董隽,蔡伟,洪宝发,王晓雄,李炎唐;雄激素最大限度阻断治疗前列腺癌的现状[J];临床泌尿外科杂志;2002年06期
2 夏国伟;;前列腺癌治疗的选择[J];临床外科杂志;2008年02期
3 王欣欣;陈雪芹;陈铌;魏强;李响;黄蕤;侯川;曾浩;;单纯去势和完全雄激素阻断治疗晚期前列腺癌疗效对比观察[J];山东医药;2009年22期
4 叶定伟;李长岭;;前列腺癌发病趋势的回顾和展望[J];中国癌症杂志;2007年03期
本文编号：2505583
本文链接：https://www.wllwen.com/yixuelunwen/mjlw/2505583.html
最近更新
教材专著
